Attila Nakeeb to Adenocarcinoma, Mucinous
This is a "connection" page, showing publications Attila Nakeeb has written about Adenocarcinoma, Mucinous.
Connection Strength
0.994
-
Simpson RE, Ceppa EP, Wu HH, Akisik F, House MG, Zyromski NJ, Nakeeb A, Al-Haddad MA, DeWitt JM, Sherman S, Schmidt CM. The Dilemma of the Dilated Main Pancreatic Duct in the Distal Pancreatic Remnant After Proximal Pancreatectomy for IPMN. J Gastrointest Surg. 2019 08; 23(8):1593-1603.
Score: 0.155
-
Carr RA, Roch AM, Shaffer K, Aboudi S, Schmidt CM, DeWitt J, Ceppa EP, House MG, Zyromski NJ, Nakeeb A, Schmidt CM. Smoking and IPMN malignant progression. Am J Surg. 2017 Mar; 213(3):494-497.
Score: 0.135
-
Roch AM, Rosati CM, Cioffi JL, Ceppa EP, DeWitt JM, Al-Haddad MA, House MG, Zyromski NJ, Nakeeb A, Schmidt CM. Intraductal papillary mucinous neoplasm of the pancreas, one manifestation of a more systemic disease? Am J Surg. 2016 Mar; 211(3):512-8.
Score: 0.126
-
Ceppa EP, Roch AM, Cioffi JL, Sharma N, Easler JJ, DeWitt JM, House MG, Zyromski NJ, Nakeeb A, Schmidt CM. Invasive, mixed-type intraductal papillary mucinous neoplasm: superior prognosis compared to invasive main-duct intraductal papillary mucinous neoplasm. Surgery. 2015 Oct; 158(4):937-44; discussion 944-5.
Score: 0.122
-
Roch AM, Barron MR, Tann M, Sandrasegar K, Hannaford KN, Ceppa EP, House MG, Zyromski NJ, Nakeeb A, Schmidt CM. Does PET with CT Have Clinical Utility in the Management of Patients with Intraductal Papillary Mucinous Neoplasm? J Am Coll Surg. 2015 Jul; 221(1):48-56.
Score: 0.120
-
Roch AM, Ceppa EP, Al-Haddad MA, DeWitt JM, House MG, Zyromski NJ, Nakeeb A, Schmidt CM. The natural history of main duct-involved, mixed-type intraductal papillary mucinous neoplasm: parameters predictive of progression. Ann Surg. 2014 Oct; 260(4):680-8; discussion 688-90.
Score: 0.115
-
Roch AM, DeWitt JM, Al-Haddad MA, Schmidt CM, Ceppa EP, House MG, Zyromski NJ, Nakeeb A, Schmidt CM. Nonoperative management of main pancreatic duct-involved intraductal papillary mucinous neoplasm might be indicated in select patients. J Am Coll Surg. 2014 Jul; 219(1):122-9.
Score: 0.111
-
Waters JA, Schmidt CM, Pinchot JW, White PB, Cummings OW, Pitt HA, Sandrasegaran K, Akisik F, Howard TJ, Nakeeb A, Zyromski NJ, Lillemoe KD. CT vs MRCP: optimal classification of IPMN type and extent. J Gastrointest Surg. 2008 Jan; 12(1):101-9.
Score: 0.071
-
Roch AM, Schneider J, Carr RA, Lancaster WP, House MG, Zyromski NJ, Nakeeb A, Schmidt CM, Ceppa EP. Are BRCA1 and BRCA2 gene mutation patients underscreened for pancreatic adenocarcinoma? J Surg Oncol. 2019 May; 119(6):777-783.
Score: 0.039